Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study Gastrointestinal Cancer Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me